- Home
- CRVS vs KMDA Comparison
CRVS vs KMDA Comparison
Compare CRVS & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- KMDA
- Stock Information
- Founded
- CRVS 2014
- KMDA 1990
- Country
- CRVS United States
- KMDA Israel
- Employees
- CRVS N/A
- KMDA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- KMDA Health Care
- Exchange
- CRVS Nasdaq
- KMDA Nasdaq
- Market Cap
- CRVS 459.0M
- KMDA 398.5M
- IPO Year
- CRVS 2016
- KMDA N/A
- Fundamental
- Price
- CRVS $7.59
- KMDA $6.95
- Analyst Decision
- CRVS Strong Buy
- KMDA Strong Buy
- Analyst Count
- CRVS 4
- KMDA 2
- Target Price
- CRVS $13.75
- KMDA $13.00
- AVG Volume (30 Days)
- CRVS 1.0M
- KMDA 77.7K
- Earning Date
- CRVS 11-04-2025
- KMDA 11-12-2025
- Dividend Yield
- CRVS N/A
- KMDA 2.88%
- EPS Growth
- CRVS N/A
- KMDA 27.97
- EPS
- CRVS N/A
- KMDA 0.32
- Revenue
- CRVS N/A
- KMDA $169,517,000.00
- Revenue This Year
- CRVS N/A
- KMDA $14.49
- Revenue Next Year
- CRVS N/A
- KMDA $10.12
- P/E Ratio
- CRVS N/A
- KMDA $21.01
- Revenue Growth
- CRVS N/A
- KMDA 9.67
- 52 Week Low
- CRVS $2.54
- KMDA $5.43
- 52 Week High
- CRVS $10.00
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CRVS 58.78
- KMDA 52.44
- Support Level
- CRVS $6.81
- KMDA $6.72
- Resistance Level
- CRVS $7.96
- KMDA $7.11
- Average True Range (ATR)
- CRVS 0.52
- KMDA 0.19
- MACD
- CRVS -0.03
- KMDA 0.03
- Stochastic Oscillator
- CRVS 67.50
- KMDA 60.68
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.